Reading 2
Reading 2
Tuberculosis: Texts
Text A
Tuberculosis
Tuberculosis is an infectious disease caused in most cases by a micro-organism called Mycobacterium tuber-
culosis. The micro-organisms usually enter the body by inhalation through the lungs. They spread from the
initial location in the lungs to other parts of the body via the blood stream, the lymphatic system, the airways or
by direct extension to other organs.
• Pulmonary tuberculosis is the most frequent form of the disease, usually comprising over 80% of cases. It is
the form of tuberculosis that can be contagious.
• Extra-pulmonary tuberculosis is tuberculosis affecting organs other than the lungs, most frequently pleura,
lymph nodes, spine and other bones and joints, genitourinary tract, nervous system, abdomen or virtually any
organ. Tuberculosis may affect any part of the body, and may even become widely disseminated throughout
the whole body.
Tuberculosis develops in the human body in two stages. The first stage occurs when an individual who is
exposed to micro-organisms from an infectious case of tuberculosis becomes infected and the second is
when the infected individual develops the disease.
Diagnosis of tuberculosis
For drug-resistant TB, a combination of antibiotics called fluoroquinolones and injectable medications such as
amikacin, kanamycin or capreomycin are generally used for 20-30 months.
Text D
• People with active TB disease should stay away from work and school until the doctor says it’s safe to return,
in order to avoid infecting others.
• Cover the mouth with a tissue when coughing and sneezing, then seal the tissue in a bag to throw it away.
• Make sure the patient’s room has adequate ventilation, so that the exhaled bacteria are carried away.
• People with active disease need to tell their doctor or health professionals about anyone they have had close
contact with, such as family, friends. © IRS Group
• Take all the medications on right time. If patient stop taking medications or skip some doses, the risk of
developing drug resistant TB is high.
Tuberculosis: Questions
Questions 1-6
For each of the questions 1-7, decide which text (A,B, C or D) the information comes from. You may use any
letter more than once.
in household setting
2. Indicators of the disease ________________________________
Questions 7-14
Answer each of the questions, 8-14, with a word or short phrase from one of the texts. Each answer may
include words, numbers or both.
8. Which is the drug used for TB skin test?
________________________________________________________________
11. How long does a patient have to take medication for drug-resistant TB?
________________________________________________________________
Questions 15-20
Complete each of the sentences, 15-20, with a word or a short phrase from one of the texts. Each answer may
include words, numbers or both.
15. The disease advances beyond the _____________________________ to affect various areas.
19. _____________________________ is suspected on patients who visit the health sector on their own interest.
END OF PART A
Health Surveillance
As part of the monitoring system, health surveillance should be undertaken if appropriate. The health of
employees exposed to hazardous substances can be affected through absorption into the body. The
absorption route can be inhalation, by ingestion, through the skin or a combination of these. When inside
the body the substances are metabolised. Metabolites can target various organs of the body which can
thereby be harmed. Health surveillance therefore requires biological monitoring. At its simplest this could
be a skin inspection ensuring no dermatitic changes have occurred as a result of exposure to an irritant,
through to lung function tests and urine, breath or blood analysis. The criteria used to decide which type of
surveillance is appropriate depend on whether a test is available. Tributyl tin oxide was once used as a
timber preservation treatment; however, it was not known how it was metabolized in the body and therefore
no appropriate test existed. The potential for it to cause harm could not be eradicated and, as many
occupational diseases have a long latency period - up to 40 years for asbestosis, for example - tributyl tin
oxide was withdrawn from use.
Airborne Precautions
Airborne precautions prevent transmission of infectious disease that are spread by airborne droplets (= 5
microns) that remain infectious and suspended in air for long periods of time over long distances and can
be widely dispersed by air currents. Airborne precautions include:
Private room with monitored negative pressure ventilation of 6-12 air exchanges per hour; airborne infec-
tion isolation room (AIIR) preferred © IRS Group
After a four-week course of treatment with a protein called ob, the fat simply falls off, leaving vastly overweight
mice slim, active and sensible eaters. If the protein has the same effect on people, it could be the miracle cure
millions have been waiting for. That, at least, is the theory. But sceptics warn that too little is known about the
way the human version of the ob protein works to be sure that extra doses would help people to lose weight.
But when the results of the tests were leaked last week, Amgen, the Californian biotechnology company
which owns the exclusive rights to develop products based on the protein, saw an overnight jump in its share
prices.
Last December, a team led by Jeffrey Friedman and his colleagues at the Howard Hughes Medical Institute at
the Rockefeller University, New York discovered a gene which they called ob. In mice, a defect in this gene
makes them grow hugely obese. Humans have an almost identical gene, suggesting that the product of the
gene – the ob protein – plays a part in appetite control. The ob protein is a hormone, which Friedman has
dubbed leptin. In April, Amgen, which is based in Thousand Oaks, California, paid the institute $20 million for
exclusive rights to develop products based on the discovery. Amgen will carry out safety tests on the protein
in animals next year, and hopes to begin clinical trials on people within a year.
The excitement began last week when the journal Science published the findings of three groups which have
been working on the protein. The results in obese mice with a defective gene that prevents them making the
protein were dramatic. Mary Ann Pelleymounter and her colleagues at Amgen gave obese mice shots of the
protein every day for a month. Those on the highest dose lost an average of 22 per cent of their weight. Before
treatment, these mice overate, had lower metabolic rates than normal, lower temperatures, and raised levels
of insulin and glucose in their blood” says Pelleymounter. “The protein brought all these back to normal
levels,” she says.
More significantly, in terms of the potential for a human slimming drug, the treatment also worked on normal
mice, which lost what little spare fat they had. They lost between 3 and 5 per cent of their bodyweight, almost
all of it in the form of fat, according to Pelleymounter. This is important because no one has identified a
mutation in the human ob gene that might lead to obesity, suggesting that whatever the cause of obesity, the
ob protein might still help people lose weight. Friedman and his team carried out similar experiments. In just
one month, their obese mice shed around half their body fat. In the average obese mouse, fat makes up about
60 per cent of body weight. Treated mice lost their appetite. Within a few days they were eating about 40 per
cent as much as untreated animals. Their fat practically melted away, falling to 28 per cent of their body
weight after a month. In normal mice, treatment reduced the amount of fat from an average of 12.22 per cent
of body weight to a spare 0.67 per cent.
The third group of researchers from the Swiss pharmaceuticals company Hoffmann-La Roche, are more
sceptical about how significant the ob protein might be in treating obesity. From their studies, they conclude
that the protein is just one of many factors that control appetite and weight. “This is a very important signal,
but it’s one of several,” says Arthur Campfield, who led the team. Campfield doubts whether the ob protein
alone will have much effect in overweight humans. His team hopes to unravel the whole signalling system that
regulates weight, and is particularly keen to find the receptor in the brain that responds to the ob hormone.
Hoffman-La Roche, excluded by the Amgen licence deal from developing products based on the ob protein
itself, hopes to develop pills that interfere with the message pathways in appetite control.
Stephen Bloom, professor of endocrinology at London’s Hammersmith Hospital, agrees. “I think the work with
ob is a major advance, but we’ve not got the tablet yet. That will come when people have made a pill that
stimulates the ob receptor in the brain so it switches off appetite.” Even Pelleymounter at Amgen cautions
against overoptimism at this stage. “We don’t know whether it would be true that people would lose weight,
but you can predict from mice that it would have some positive effect,” she says. “However, I don’t think obese
people should hold out for this. They should carry on with their exercises and dieting.”
A written
B named
C defined
D proved
10. A study by Mary Ann Pellymounter and her colleagues found that
A the ob protein caused subjects in the study to decrease their metabolic rate
B the ob protein cased people to lose about twenty percent of their weight
C a deficiency in the ob protein had caused obesity in the subjects
D a defective ob gene resulted in the production of the ob protein
A strong
B lazy
C slow
D sick
13. The research from Hoffman-La Roche are less confident of the protein’s importance because
Butter, as anyone who has not been living in a cave for the past ten years has probably heard, contains a lot
of saturated fat, which increases the levels of cholesterol in the blood. Margarine, on the other hand, is made
from vegetable oils, which contain cholesterol-lowering polyunsaturated fat. So switching to a diet with only
vegetable fats should lower cholesterol levels, right? ‘Wrong,’ says Margaret A Flynn, a nutritionist at the
University of Missouri. When she performed the experiment with a group of 71 faculty members – switching in
both directions – she found that ‘basically it made no difference whether they ate margarine or butter.’ The
reason, according to a growing group of nutritionists, could be partially hydrogenated fats. Recent studies
suggest that such fats might actually alter cholesterol levels in the blood in all the wrong ways, lowering the
‘good’ high-density lipoprotein and increasing the ‘bad’ low-density lipoprotein.
Partially hydrogenated fats are made by reacting polyunsaturated oils with hydrogen. The addition of hydrogen
turns the oils solid, and some of their polyunsaturated fat is turned into trans monounsaturated fats.
Monounsaturated fat is generally perceived as good, but things are not so simple. ‘Trans monounsaturates
act in the body like saturated fats,’ says Fred A Kummerow, a food chemist at the University of Illinois at
Urbana-Champaign. ‘Almost all naturally occurring monounsaturated fat is of the cis variety, which is more
like polyunsaturated fat.’ Flynn’s study is not the first to raise questions about trans fatty acids. Ten years
ago a Canadian government task force noted the apparent cholesterol-raising effects of trans fats and requested
margarine manufacturers to reduce the amounts – which can easily be done by altering the conditions of the
hydrogenation reaction.
Last August two Dutch researchers, Ronald P Mensink and Martijn B Katan, published a study in the New
England Journal of Medicine that showed eating a diet rich in trans fats increased low-density lipoprotein and
decreased levels of high-density lipoprotein. In an editorial accompanying the study, Scott M Grundy, a lipid
researcher at the University of Texas Southwestern Medical Center at Dallas, wrote that the ability of trans
fatty acids to increase low-density lipoprotein ‘in itself justifies their reduction in the diet.’ Grundy called for
changes in labelling regulations so that cholesterol-raising fatty acids, including trans monounsaturates, are
grouped together. James I Cleeman, co-ordinator of the National Cholesterol Education Program, disagrees.
‘To raise a red flag is premature,’ he says. ‘Mensink’s audience is the research community – the public
needs useable simplifications.’ Cleeman points out that the subjects in Mensink and Katan’s study ate
relatively large amounts of trans fats. He believes more typical consumption levels should be investigated
before any change in recommendations is warranted.
Furthermore, Cleeman notes that studies like Flynn’s are hard to interpret because subjects were allowed to
eat as they pleased. Flynn’s study, published this month in the Journal of the American College of Nutrition,
found considerable variability among subjects in their blood lipid profiles. ‘The only way to study the question
properly is in a metabolic ward,’ Cleeman says. ‘Trans fats are a wonderful example of an issue that’s not
ready for prime time.’ Edward A Emken, a specialist on trans fats at the Agricultural Research Service in
Peoria, Illinois, also downplays the concern but for different reasons. Although Mary G Enig, a nutritional
researcher at the University of Maryland, has estimated American adults consume 19 grams of trans fat per
day, Emken thinks that figure is too high. According to his calculations, eliminating trans fatty acids from the
Emken, together with Lisa C Hudgins and Jules Hirsch, has performed a study to be published in the American
Journal of Clinical Nutrition that finds no association between levels of trans fats in fat tissue in humans and
their cholesterol profiles. To Emken, that suggests trans fats are not a major threat for most people.
Nevertheless, trans fats seem destined for more limelight. ‘How can one defend having cholesterol and saturated
and unsaturated fats listed on food labels but not allow public access to trans information when such fats
behave like saturates?’ asks Bruce J Holub, a biochemist at the University of Guelph in Ontario. ‘At the very
least, one has to ask whether cholesterol-free claims should be allowed on high-trans products.’
A eating butter is not as dangerous for cholesterol levels as was previously thought
B cholesterol levels in humans can be noticeably reduced by cutting out animal fats
C eating margarine is s healthier option than eating butter
D the benefits of using only vegetable fats in the human diet are arguable